HEPLISAV-B achieved preliminary quarterly net product revenue of $71M for the fourth quarter of 2024, an increase of 39% compared to $51M for the fourth quarter of 2023. Q4 revenue consensus $71.71M.
HEPLISAV-B achieved preliminary quarterly net product revenue of $71M for the fourth quarter of 2024, an increase of 39% compared to $51M for the fourth quarter of 2023. Q4 revenue consensus $71.71M.